Who are bivalirudin + clopidogrel + aspirin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Active Comparator: Rivaroxaban+Clopidogrel, enoxaparin + clopidogrel + aspirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bivalirudin-clopidogrel-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

bivalirudin + clopidogrel + aspirin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bivalirudin + clopidogrel + aspirin (bivalirudin + clopidogrel + aspirin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant + antiplatelet combination. Area: Cardiovascular.

marketed Anticoagulant + antiplatelet combination Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

bivalirudin + clopidogrel + aspirin (bivalirudin + clopidogrel + aspirin) — Centre Hospitalier de PAU. This combination inhibits blood clotting through three complementary pathways: bivalirudin directly blocks thrombin, while clopidogrel and aspirin inhibit platelet aggregation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
bivalirudin + clopidogrel + aspirin TARGET	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Active Comparator: Rivaroxaban+Clopidogrel	Active Comparator: Rivaroxaban+Clopidogrel	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Anticoagulant + Antiplatelet combination	Factor Xa; P2Y12 receptor
enoxaparin + clopidogrel + aspirin	enoxaparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Factor Xa, Factor IIa, P2Y12 receptor, cyclooxygenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant + antiplatelet combination class)

Centre Hospitalier de PAU · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bivalirudin + clopidogrel + aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/bivalirudin-clopidogrel-aspirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab